David Sinclair, a prominent genetics professor at Harvard Medical School, has announced that human trials for age reversal technology are set to begin soon. Sinclair, known for his groundbreaking work in aging research, claims that aging is not an inevitable process and can potentially be reversed through gene therapy. The trials will initially focus on the eye, chosen for its safety as an enclosed system, with the aim of rejuvenating the optic nerve by introducing and activating specific genes. Sinclair's research suggests that reversing aging could lead to cures for major diseases such as Alzheimer's, cancer, and heart disease. He believes that understanding and reversing aging could have the most significant impact on human health in history. The trials mark a significant milestone in longevity research, with the potential to transform human life expectancy and fundamentally change health perspectives. The concept of resetting cellular age is central to Sinclair's work, with claims that the age of cells can be safely reset by about 75%. This approach is grounded in the information theory of aging, which remains unchallenged and provides a scientific foundation for the potential to reverse aging. Sinclair's work underscores the transformative potential of gene therapy in addressing age-related conditions.